25 Biotechnology Stocks to Buy Now

25 Biotechnology Stocks to Buy Now

25 Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

Amgen Inc. (AMGN) earns a B this week, jumping up from last week’s grade of C. Amgen Inc. discovers, develops, manufactures, and markets medicines for serious illnesses. The company also gets A’s in return on equity. For more information, get Portfolio Grader’s complete analysis of AMGN stock.

The rating of China Biologic Products, Inc. (CBPO) moves up this week, rising from a C to a B. China Biologic Products, Inc. is a biopharmaceutical company that engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers. The company also gets A’s in return on equity. For more information, get Portfolio Grader’s complete analysis of CBPO stock.

This week, Medivation, Inc.’s (MDVN) ratings are up from a B last week to a A. Medivation, Inc. acquires, develops, and sells or partners biomedical technologies in the early development stage of the research and development process. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of MDVN stock.

Galapagos NV Sponsored ADR (GLPG) is seeing ratings go up from a C last week to a B this week. The company also gets A’s in sales growth, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of GLPG stock.

This week, AbbVie, Inc. (ABBV) pushes up from a C to a B rating. AbbVie, Inc. a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. The company also gets A’s in operating margin growth and return on equity. For more information, get Portfolio Grader’s complete analysis of ABBV stock.

Ophthotech Corp. (OPHT) improves from a C to a B rating this week. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of OPHT stock.

Sarepta Therapeutics, Inc.’s (SRPT) ratings are looking better this week, moving up to a B from last week’s C. Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of unique RNA-based therapeutics for the treatment of both rare and infectious diseases. For more information, get Portfolio Grader’s complete analysis of SRPT stock.

This is a strong week for Seattle Genetics, Inc. (SGEN). The company’s rating climbs to B from the previous week’s C. Seattle Genetics, Inc. is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company also gets A’s in sales growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of SGEN stock.

Cepheid (CPHD) shows solid improvement this week. The company’s rating rises from a C to a B. Cepheid is a molecular diagnostics company that engages in developing, manufacturing, and marketing integrated systems for testing in the clinical market, as well as for application in legacy biothreat, industrial, and partner markets. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of CPHD stock.

Tobira Therapeutics, Inc. (TBRA) boosts its rating from a D to a B this week. For more information, get Portfolio Grader’s complete analysis of TBRA stock.

Genomic Health, Inc. (GHDX) gets a higher grade this week, advancing from a C last week to a B. Genomic Health, Inc. is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. For more information, get Portfolio Grader’s complete analysis of GHDX stock.

Blueprint Medicines Corp. (BPMC) earns a B this week, jumping up from last week’s grade of C. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of BPMC stock.

Vitae Pharmaceuticals, Inc. (VTAE) is seeing ratings go up from a C last week to a B this week. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of VTAE stock.

This week, Lexicon Pharmaceuticals, Inc.’s (LXRX) ratings are up from a C last week to a B. Lexicon Pharmaceuticals, Inc. researches treatments for diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of LXRX stock.

Ironwood Pharmaceuticals, Inc. Class A (IRWD) gets a higher grade this week, advancing from a C last week to a B. Ironwood Pharmaceuticals, Inc. Class A discovers, develops, manufactures, and commercializes marketed drugs. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of IRWD stock.

ARIAD Pharmaceuticals, Inc. (ARIA) improves from a B to a A rating this week. ARIAD Pharmaceuticals, Inc. is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. The company also gets A’s in sales growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ARIA stock.

This is a strong week for OPKO Health, Inc. (OPK). The company’s rating climbs to B from the previous week’s C. OPKO Health, Inc. is involved in the discovery, development, and commercialization of pharmaceutical products, vaccines, and diagnostic products. The company also gets A’s in sales growth and earnings surprise. For more information, get Portfolio Grader’s complete analysis of OPK stock.

Raptor Pharmaceutical Corp.’s (RPTP) ratings are looking better this week, moving up to a B from last week’s D. Raptor Pharmaceutical Corp. researches existing drugs to improve them through specialized drug targeting methods and formulation changes. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of RPTP stock.

Nexvet Biopharma PLC (NVET) boosts its rating from a C to a B this week. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of NVET stock.

Lpath, Inc. (LPTN) shows solid improvement this week. The company’s rating rises from a C to a B. Lpath, Inc. is a drug discovery company with a focus on bioactive signaling lipids as targets for treating and diagnosing human diseases. For more information, get Portfolio Grader’s complete analysis of LPTN stock.

This week, Venaxis, Inc. (APPY) pushes up from a C to a B rating. Venaxis, Inc. develops and commercializes products for unmet diagnostic and therapeutic needs. For more information, get Portfolio Grader’s complete analysis of APPY stock.

The rating of Rigel Pharmaceuticals, Inc. (RIGL) moves up this week, rising from a C to a B. Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. The company also gets A’s in sales growth and earnings surprise. For more information, get Portfolio Grader’s complete analysis of RIGL stock.

This week, Immunomedics, Inc.’s (IMMU) ratings are up from a C last week to a B. Immunomedics, Inc. develops, manufactures, and sells diagnostic imaging and therapeutic products. For more information, get Portfolio Grader’s complete analysis of IMMU stock.

PharmAthene, Inc. (PIP) is seeing ratings go up from a B last week to a A this week. PharmAthene, Inc. develops biological and chemical defense products. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of PIP stock.

This is a strong week for Galectin Therapeutics Inc. (GALT). The company’s rating climbs to B from the previous week’s D. Galectin Therapeutics Inc. is a drug development company. For more information, get Portfolio Grader’s complete analysis of GALT stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/10/25-biotechnology-stocks-to-buy-now/.

©2019 InvestorPlace Media, LLC